Financhill
Sell
34

RCEL Quote, Financials, Valuation and Earnings

Last price:
$5.73
Seasonality move :
0.45%
Day range:
$5.61 - $5.97
52-week range:
$4.71 - $14.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.07x
P/B ratio:
40.83x
Volume:
266.7K
Avg. volume:
332.5K
1-year change:
-35.15%
Market cap:
$150.7M
Revenue:
$64.3M
EPS (TTM):
-$2.19

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RCEL
AVITA Medical
$22.4M -$0.23 47.51% -61.01% $16.95
CATX
Perspective Therapeutics
$170.4K -$0.29 -- -55.87% $14.1071
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$375.7K -$0.05 6.24% -40.63% $2.94
VTAK
Catheter Precision
$310K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.4M -$0.02 4.73% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RCEL
AVITA Medical
$5.70 $16.95 $150.7M -- $0.00 0% 2.07x
CATX
Perspective Therapeutics
$3.9800 $14.1071 $295.4M -- $0.00 0% 28.05x
RVP
Retractable Technologies
$0.68 -- $20.4M -- $0.00 0% 0.60x
VNRX
VolitionRX
$0.67 $2.94 $68.8M -- $0.00 0% 46.02x
VTAK
Catheter Precision
$0.24 -- $2.7M 0.40x $0.00 0% 2.77x
XTNT
Xtant Medical Holdings
$0.66 $1.75 $91.3M -- $0.00 0% 0.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RCEL
AVITA Medical
112.39% -0.697 19.27% 1.65x
CATX
Perspective Therapeutics
-- 1.363 -- --
RVP
Retractable Technologies
1.48% -0.677 12.06% 4.40x
VNRX
VolitionRX
-29.91% 3.387 11.38% 0.34x
VTAK
Catheter Precision
17.75% -1.532 53.57% 0.13x
XTNT
Xtant Medical Holdings
43.24% 1.491 51.14% 0.96x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RCEL
AVITA Medical
$15.7M -$11.8M -102.9% -415.55% -68.15% -$10.5M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
RVP
Retractable Technologies
-$1.9K -$3.2M -25.99% -26.39% -122.86% -$1.6M
VNRX
VolitionRX
-- -$5.4M -- -- -2183.56% -$4.3M
VTAK
Catheter Precision
$132K -$3.5M -126.5% -137.84% -3300.7% -$2.3M
XTNT
Xtant Medical Holdings
$20.2M $1.1M -15.44% -26.62% 3.28% $87K

AVITA Medical vs. Competitors

  • Which has Higher Returns RCEL or CATX?

    Perspective Therapeutics has a net margin of -74.86% compared to AVITA Medical's net margin of --. AVITA Medical's return on equity of -415.55% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About RCEL or CATX?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 196.53%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 254.45%. Given that Perspective Therapeutics has higher upside potential than AVITA Medical, analysts believe Perspective Therapeutics is more attractive than AVITA Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is RCEL or CATX More Risky?

    AVITA Medical has a beta of 1.518, which suggesting that the stock is 51.797% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

  • Which is a Better Dividend Stock RCEL or CATX?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or CATX?

    AVITA Medical quarterly revenues are $18.5M, which are larger than Perspective Therapeutics quarterly revenues of --. AVITA Medical's net income of -$13.9M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, AVITA Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.07x versus 28.05x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.07x -- $18.5M -$13.9M
    CATX
    Perspective Therapeutics
    28.05x -- -- -$18.2M
  • Which has Higher Returns RCEL or RVP?

    Retractable Technologies has a net margin of -74.86% compared to AVITA Medical's net margin of -126.59%. AVITA Medical's return on equity of -415.55% beat Retractable Technologies's return on equity of -26.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    RVP
    Retractable Technologies
    -0.02% -$0.35 $77.8M
  • What do Analysts Say About RCEL or RVP?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 196.53%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that AVITA Medical has higher upside potential than Retractable Technologies, analysts believe AVITA Medical is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    RVP
    Retractable Technologies
    0 0 0
  • Is RCEL or RVP More Risky?

    AVITA Medical has a beta of 1.518, which suggesting that the stock is 51.797% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

  • Which is a Better Dividend Stock RCEL or RVP?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or RVP?

    AVITA Medical quarterly revenues are $18.5M, which are larger than Retractable Technologies quarterly revenues of $8.3M. AVITA Medical's net income of -$13.9M is lower than Retractable Technologies's net income of -$10.5M. Notably, AVITA Medical's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.07x versus 0.60x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.07x -- $18.5M -$13.9M
    RVP
    Retractable Technologies
    0.60x -- $8.3M -$10.5M
  • Which has Higher Returns RCEL or VNRX?

    VolitionRX has a net margin of -74.86% compared to AVITA Medical's net margin of -2201.34%. AVITA Medical's return on equity of -415.55% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    VNRX
    VolitionRX
    -- -$0.06 -$22.6M
  • What do Analysts Say About RCEL or VNRX?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 196.53%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 340.32%. Given that VolitionRX has higher upside potential than AVITA Medical, analysts believe VolitionRX is more attractive than AVITA Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    VNRX
    VolitionRX
    3 1 0
  • Is RCEL or VNRX More Risky?

    AVITA Medical has a beta of 1.518, which suggesting that the stock is 51.797% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

  • Which is a Better Dividend Stock RCEL or VNRX?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or VNRX?

    AVITA Medical quarterly revenues are $18.5M, which are larger than VolitionRX quarterly revenues of $246.4K. AVITA Medical's net income of -$13.9M is lower than VolitionRX's net income of -$5.4M. Notably, AVITA Medical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.07x versus 46.02x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.07x -- $18.5M -$13.9M
    VNRX
    VolitionRX
    46.02x -- $246.4K -$5.4M
  • Which has Higher Returns RCEL or VTAK?

    Catheter Precision has a net margin of -74.86% compared to AVITA Medical's net margin of -2828.67%. AVITA Medical's return on equity of -415.55% beat Catheter Precision's return on equity of -137.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    VTAK
    Catheter Precision
    92.31% -$0.36 $9.6M
  • What do Analysts Say About RCEL or VTAK?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 196.53%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 727.82%. Given that Catheter Precision has higher upside potential than AVITA Medical, analysts believe Catheter Precision is more attractive than AVITA Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    VTAK
    Catheter Precision
    0 0 0
  • Is RCEL or VTAK More Risky?

    AVITA Medical has a beta of 1.518, which suggesting that the stock is 51.797% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

  • Which is a Better Dividend Stock RCEL or VTAK?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or VTAK?

    AVITA Medical quarterly revenues are $18.5M, which are larger than Catheter Precision quarterly revenues of $143K. AVITA Medical's net income of -$13.9M is lower than Catheter Precision's net income of -$4M. Notably, AVITA Medical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.07x versus 2.77x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.07x -- $18.5M -$13.9M
    VTAK
    Catheter Precision
    2.77x 0.40x $143K -$4M
  • Which has Higher Returns RCEL or XTNT?

    Xtant Medical Holdings has a net margin of -74.86% compared to AVITA Medical's net margin of 0.18%. AVITA Medical's return on equity of -415.55% beat Xtant Medical Holdings's return on equity of -26.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    XTNT
    Xtant Medical Holdings
    61.52% -- $77.3M
  • What do Analysts Say About RCEL or XTNT?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 196.53%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 167.18%. Given that AVITA Medical has higher upside potential than Xtant Medical Holdings, analysts believe AVITA Medical is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    XTNT
    Xtant Medical Holdings
    1 0 1
  • Is RCEL or XTNT More Risky?

    AVITA Medical has a beta of 1.518, which suggesting that the stock is 51.797% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

  • Which is a Better Dividend Stock RCEL or XTNT?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or XTNT?

    AVITA Medical quarterly revenues are $18.5M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. AVITA Medical's net income of -$13.9M is lower than Xtant Medical Holdings's net income of $58K. Notably, AVITA Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.07x versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.07x -- $18.5M -$13.9M
    XTNT
    Xtant Medical Holdings
    0.73x -- $32.9M $58K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock